Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting
May 23 2024 - 5:00PM
Merus Announces Publication of Abstracts for Presentation at the
2024 ASCO® Annual Meeting
Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a
clinical-stage oncology company developing innovative, full-length
multispecific antibodies (Biclonics® and Triclonics®), today
announced the publication of an abstract regarding MCLA-145 and an
abstract regarding MCLA-129 at the 2024 American Society of
Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago
May 31-June 4, 2024. Both abstracts can be found on the 2024 ASCO®
website.
“We continue to be proud of our Multiclonics® technology
platforms' ability to develop bispecific antibodies for clinical
investigation with the potential to impact patients’ lives,” said
Bill Lundberg, M.D., President, Chief Executive Officer of Merus.
“MCLA-129 continues to show strong monotherapy activity in EGFR
mutant non-small cell lung cancer, and MCLA-145 is now the fourth
molecule based on our technology to demonstrate clinical activity.
We are looking forward to providing additional detail at 2024
ASCO®.”
MCLA-145 (CD137 x PD-L1 Biclonics®): Solid
Tumors Interim data included in the abstract describe data
from patients (pts) with advanced/metastatic solid tumors who
received MCLA-145 as monotherapy every two weeks (Q2W) in 21 day
cycles or every three weeks (Q3W) in 28 day cycles. Pts treated
with the combination of MCLA-145 and pembrolizumab had cancers that
either relapsed after PD-(L)1 therapies or were immunotherapy
naïve.
Rapid oral presentation title: Phase I study of
MCLA-145, a bispecific antibody targeting CD137 and PD-L1, in solid
tumors, as monotherapy or in combination with
pembrolizumabObservations in the abstract include:
- As of a December 4, 2023 data cutoff date, 72 pts with multiple
cancer types were treated; 25% of pts had non-small cell lung
cancer (NSCLC); 3 pts were continuing combination therapy
- Monotherapy: 53 pts were treated across 8 dose levels
- 47 pts 0.4-75 mg Q2W
- 6 pts 40 mg Q3W
- The recommended dose for expansion (RDE) was established at
40 mg Q3W
- In 52 pts evaluable for response
- 5 partial responses (PRs) were observed in a variety of tumor
types including: glioblastoma (ongoing>3 years), sarcoma,
cervical, anal, and gastric cancer (treated for 2-11 month (mo)) by
Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. per
investigator assessment
- Combination: 19 pts were treated with MCLA-145 10, 25 or 40 mg
plus pembrolizumab Q3W
- The RDE was established at 40 mg Q3W
- In 19 pts evaluable for response
- 1 complete response was observed in PD-L1+ NSCLC (treated 6+
mo) and 1 PR in Merkel cell carcinoma (treated 12+ mo); both after
prior immunotherapy
- 68% disease control rate was observed
- MCLA-145 monotherapy or in combination with pembrolizumab had a
well-tolerated and manageable safety profile at the RDE of 40 mg
Q3W
Presentation Details: Abstract
#: 2520 Session Title: Developmental
Therapeutics—Immunotherapy Session Date and
Time: June 2, 2024, 11:30 a.m.-1:00 p.m. CT
MCLA-129 (EGFR x c-MET Biclonics®): Solid
Tumors The abstract describes a cohort of patients with
advanced/metastatic METex14 NSCLC previously treated with standard
therapies, and who were either c-MET TKI-naïve or who progressed on
c-MET TKI.
Safety and efficacy data will be included in the poster
presentation at 2024 ASCO®.
Poster presentation title: Efficacy and safety
of MCLA-129, an anti-EGFR/c-MET bispecific antibody, in
non-small-cell lung cancer (NSCLC) with c-MET exon 14 skipping
mutations (METex14)Presentation Details:
Abstract #: 8583 Session
Title: Lung Cancer—Non-Small Cell
Metastatic Session Date and Time: June 3,
2024, 1:30-4:30 p.m. CT
As full presentations become available at the 2024 ASCO® Annual
Meeting, they will contemporaneously be available on the Merus
website.
About Merus N.V. Merus is a
clinical-stage oncology company developing innovative full-length
human bispecific and trispecific antibody therapeutics, referred to
as Multiclonics®. Multiclonics® are manufactured using industry
standard processes and have been observed in preclinical and
clinical studies to have several of the same features of
conventional human monoclonal antibodies, such as long half-life
and low immunogenicity. For additional information, please visit
Merus’ website, https://www.merus.nl and
https://twitter.com/MerusNV.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release that do not relate to matters of
historical fact should be considered forward-looking statements,
including without limitation statements regarding the clinical
development of our clinical candidates, including MCLA-145 and
MCLA-129, future clinical trial results or interim data, clinical
activity and safety profile, and development plans in the on-going
trials and described in forthcoming posters or presentations; the
ability of our Multiclonics® platforms' to develop bispecific
antibodies for clinical investigation having potential to impact
patients’ lives; the future activity of MCLA-129 in EGFR mutant
non-small cell lung cancer or MCLA-145 in solid tumors; and future
development of these assets. We are looking forward to providing
additional detail at 2024 ASCO®. These forward-looking statements
are based on management’s current expectations. These
forward-looking statements are based on management’s current
expectations. These statements are neither promises nor guarantees,
but involve known and unknown risks, uncertainties and other
important factors that may cause our actual results, performance or
achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements, including, but not limited to, the
following: our need for additional funding, which may not be
available and which may require us to restrict our operations or
require us to relinquish rights to our technologies or Biclonics®,
Triclonics® and multispecific antibody candidates; potential delays
in regulatory approval, which would impact our ability to
commercialize our product candidates and affect our ability to
generate revenue; the lengthy and expensive process of clinical
drug development, which has an uncertain outcome; the unpredictable
nature of our early stage development efforts for marketable drugs;
potential delays in enrollment of patients, which could affect the
receipt of necessary regulatory approvals; our reliance on third
parties to conduct our clinical trials and the potential for those
third parties to not perform satisfactorily; impacts of the market
volatility; we may not identify suitable Biclonics® or bispecific
antibody candidates under our collaborations or our collaborators
may fail to perform adequately under our collaborations; our
reliance on third parties to manufacture our product candidates,
which may delay, prevent or impair our development and
commercialization efforts; protection of our proprietary
technology; our patents may be found invalid, unenforceable,
circumvented by competitors and our patent applications may be
found not to comply with the rules and regulations of
patentability; we may fail to prevail in potential lawsuits for
infringement of third-party intellectual property; and our
registered or unregistered trademarks or trade names may be
challenged, infringed, circumvented or declared generic or
determined to be infringing on other marks.
These and other important factors discussed under the caption
“Risk Factors” in our Annual Report on Form 10-Q for the quarter
ended March 31, 2024 filed with the Securities and Exchange
Commission, or SEC, on May 8, 2024, and our other reports filed
with the SEC, could cause actual results to differ materially from
those indicated by the forward-looking statements made in this
press release. Any such forward-looking statements represent
management’s estimates as of the date of this press release. While
we may elect to update such forward-looking statements at some
point in the future, we disclaim any obligation to do so, even if
subsequent events cause our views to change, except as required
under applicable law. These forward-looking statements should not
be relied upon as representing our views as of any date subsequent
to the date of this press release.
Multiclonics®, Biclonics® and Triclonics® are registered
trademarks of Merus N.V.
Merus NV (TG:2GH)
Historical Stock Chart
From Aug 2024 to Sep 2024
Merus NV (TG:2GH)
Historical Stock Chart
From Sep 2023 to Sep 2024